Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt Benckiser HealthcarefiledCriticalReckitt Benckiser Healthcare
Publication of MY120190ApublicationCriticalpatent/MY120190A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
AN ANALGESIC COMPOSITION IN PARENTERAL UNIT DOSAGE FORM OR IN A UNIT DOSAGE FORM SUITABLE FOR DELIVERY VIA THE MUCOSA COMPRISING AN AMOUNT OF BUPRENORPHINE WHICH IS LESS THAN THE CLINICAL DOSE REQUIRED TO ACHIEVE PAIN RELIEF AND AN AMOUNT OF NALOXONE SUCH THAT THE RATIO BY WEIGHT OF BUPRENORPHINE TO NALOXONE IS IN THE RANGE OF FROM 12.5:1 TO 27.5:1, OR AN AMOUNT OF NALTREXONE OR NALMEFENE SUCH THAT THE RATIO BY WEIGHT OF BUPRENORPHINE TO NALTREXONE OR NALMEFENE IS IN THE RANGE OF FROM 12.5:1 TO 22.5:1, WHEREBY THE ANALGESIC ACTION OF THE BUPRENORPHINE IS POTENTIATED BY THE LOW DOSE OF NALOXONE, NALTREXONE OR NALMEFENE.
MYPI200054442000-01-142000-11-21Potentiation of the analgesic effect of buprenorphine
MY120190A
(en)